134 related articles for article (PubMed ID: 16302698)
1. Clinical effect of urokinase on chronic glomerulonephritis (group study).
Abe T
New Istanbul Contrib Clin Sci; 1978 Mar; 12(2):123-32. PubMed ID: 16302698
[No Abstract] [Full Text] [Related]
2. [The levels of fibrinopeptide A and fibrinopeptide B beta in the urine from patients with chronic glomerulonephritis during urokinase therapy].
Miura M; Tomino Y; Inoue W; Tamura S; Nomoto Y; Sakai H; Itoh K
Rinsho Byori; 1985 Jun; 33(6):652-6. PubMed ID: 4032804
[No Abstract] [Full Text] [Related]
3. [Studies on the fibrinolytic therapy in patients with various renal diseases. Clinical effects of urokinase (author's transl)].
Takasaki H; Shibata M
Nihon Jinzo Gakkai Shi; 1981 Sep; 23(9):1271-80. PubMed ID: 7035725
[No Abstract] [Full Text] [Related]
4. [A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome].
Konishi K; Kato E; Iyori S; Higashi F
Nihon Jinzo Gakkai Shi; 1982 Apr; 24(4):429-44. PubMed ID: 6750187
[No Abstract] [Full Text] [Related]
5. [Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan].
Tomura S; Takeuchi J; Tanaka K
Nihon Jinzo Gakkai Shi; 1984 Jan; 26(1):97-121. PubMed ID: 6376892
[No Abstract] [Full Text] [Related]
6. [Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)].
Koitabashi Y; Maruyama T; Ikoma M; Miyaji Y; Yamada K; Shimizu K
Rinsho Ketsueki; 1982 Mar; 23(3):309-18. PubMed ID: 7050462
[No Abstract] [Full Text] [Related]
7. [A study of fibrinolytic therapy in glomerulonephritis and nephrotic syndrome. III. Indication, time to start therapy and criteria of effect (author's transl)].
Sato M; Nakazora H; Ohfuji T
Nihon Jinzo Gakkai Shi; 1977 Sep; 19(9):717-31. PubMed ID: 599731
[No Abstract] [Full Text] [Related]
8. [Urinary fibrinolytic enzyme activity in systemic diseases and chronic glomerulonephritis].
Palienko IA; Belitskaia GA
Vrach Delo; 1988 Feb; (2):71-3. PubMed ID: 3381527
[No Abstract] [Full Text] [Related]
9. [Blood phospholipids in patients with different clinical manifestations of chronic glomerulonephritis and preserved kidney function].
Riabov SI; Kulikova AI; Mitrofanova OV
Ter Arkh; 1995; 67(2):51-4. PubMed ID: 7725261
[No Abstract] [Full Text] [Related]
10. [Membranoproliferative glomerulonephritis and allied glomerulonephritis: development, treatment and prognosis (author's transl)].
Dohi K; Nakamoto Y; Kida H; Abe T; Fujioka M; Hattori N
Nihon Jinzo Gakkai Shi; 1981 Feb; 23(2):195-207. PubMed ID: 6166777
[No Abstract] [Full Text] [Related]
11. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis].
Bobkova IN; Kozlovskaia LV; Rameeva AS; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2007; 79(6):10-5. PubMed ID: 17684960
[TBL] [Abstract][Full Text] [Related]
12. [Blood volumes in patients with chronic glomerulonephritis].
Diadyk AI; Siniachenko OV; Bagriĭ AE; Iarovaia NF; Shchukina EV
Ter Arkh; 1992; 64(12):94-6. PubMed ID: 1292145
[No Abstract] [Full Text] [Related]
13. Effect of oral urokinase and its clinical application.
Abe T; Kazama M; Naito I; Kinoshita T; Sasaki K
New Istanbul Contrib Clin Sci; 1982; 13(3):161-70. PubMed ID: 6760114
[No Abstract] [Full Text] [Related]
14. [On the treatment of acute glomeruloinephritis with heparin. Preliminary clinical results].
Verzetti G; Busilacchi M; Pisano E; Perpignano G
Minerva Nefrol; 1966; 13(4):136-40. PubMed ID: 5996325
[No Abstract] [Full Text] [Related]
15. [Fibrin deposits in Masugi nephritis and effects of urokinase, non-steroidal anti-inflammatory agents, anti-inflammatory enzymes and prostaglandins].
Sugizaki T
Nihon Jinzo Gakkai Shi; 1983 Jul; 25(7):836-8. PubMed ID: 6663853
[No Abstract] [Full Text] [Related]
16. Urinary excretion of fibrinogen-fibrin-related antigen in glomerulonephritis: effect of indomethacin.
Dotremont G; Vermylen J; Donati MB; Van Damme B; Michielsen P
Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):829-44. PubMed ID: 4803317
[No Abstract] [Full Text] [Related]
17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
18. [Urokinase excretion and fibrinolysis in infectious kidney diseases].
Bachmann HJ; Tacke E; Haupt H
Monatsschr Kinderheilkd (1902); 1974 Jul; 122(7):567-8. PubMed ID: 4411414
[No Abstract] [Full Text] [Related]
19. [Subconjunctival injection of urokinase in the treatment of diabetic vitreous hemorrhage].
Chen XL
Zhonghua Yan Ke Za Zhi; 1983 Jan; 19(1):35-6. PubMed ID: 6406190
[No Abstract] [Full Text] [Related]
20. [Heparin treatment of acute and chronic glomerulonephritis].
Gilunova NI; Tsalenchuk IaP
Ter Arkh; 1973 May; 45(5):112-7. PubMed ID: 4768366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
